Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BMS Sighs In Relief As Opdivo Returns To Sales Growth

Jul 28 2021

• By Joseph Haas

BMS reports 16% year-over-year sales growth for Q2 2021

Related Content

Keeping Track: New Uses For Opdivo, Trodelvy; Nextstellis Introduces A Novel Estrogen

Apr 17 2021

Bristol’s Opdivo Continues Slide, But First-Line Lung Offers Optimism

Aug 06 2020

Exelixis Has Renewed Momentum Heading Into 2021

Feb 11 2021

Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors

Feb 08 2021

BMS Has A Lot Of Ground To Make Up Ahead Of Patent Expiries

Apr 30 2021

Bristol Pays Out $200m For Agenus' Preclinical Bispecific TIGIT

May 18 2021

BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

Jun 18 2021

BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients

Mar 30 2021

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Exelixis, Inc.

Genetix Biotherapeutics

Agenus Inc.

Eisai Co., Ltd.

Additional Topics

Sales & Earnings Business Strategies ImmunoOncology Companies Commercial BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window